Interpreting the latest guidelines: How to choose the correct COVID-19 antiviral
And how individualised patient management plans tackle the problem of clinical inertia
This content has been independently produced by AusDoc made possible through sponsorship from MSD.
Understanding and addressing post-pandemic apathy is crucial in the push to protect older, at-risk patients from serious disease, says Associate Professor Roy Rasalam, a clinician-researcher and trial investigator on COVID-19 vaccines, diabetes and cardiovascular disease.
